In conclusion, our study found that sacubitril/valsartan can better inhibit ventricular remodeling after myocardial infarction than valsartan and improve cardiac function, and this effect is related to inhibition of collagen synthesis by myocardial fibroblasts through downregulating TGF-β1/Smads pathway. The gene discussed is TGFB1; the disease is myocardial infarction.